GKV Capital Management Co. Inc. Takes $1.58 Million Position in Astrazeneca Plc $AZN

GKV Capital Management Co. Inc. purchased a new stake in shares of Astrazeneca Plc (NYSE:AZN) during the 4th quarter, HoldingsChannel reports. The fund purchased 9,000 shares of the company’s stock, valued at approximately $1,580,000.

Several other hedge funds also recently modified their holdings of the company. CIBC Asset Management Inc increased its position in shares of Astrazeneca by 3.7% during the 4th quarter. CIBC Asset Management Inc now owns 253,856 shares of the company’s stock valued at $44,552,000 after purchasing an additional 9,132 shares during the period. Marble Wealth LLC acquired a new position in shares of Astrazeneca during the 4th quarter valued at $586,000. Bank of New York Mellon Corp increased its position in shares of Astrazeneca by 2.6% during the 4th quarter. Bank of New York Mellon Corp now owns 1,032,000 shares of the company’s stock valued at $181,116,000 after purchasing an additional 25,833 shares during the period. Calton & Associates Inc. acquired a new position in shares of Astrazeneca during the 4th quarter valued at $412,000. Finally, Channing Global Advisors LLC increased its position in shares of Astrazeneca by 5.8% during the 4th quarter. Channing Global Advisors LLC now owns 10,682 shares of the company’s stock valued at $1,875,000 after purchasing an additional 590 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AZN has been the topic of several research analyst reports. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Barclays reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, May 13th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Thursday, May 21st. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Astrazeneca has a consensus rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Stock Performance

AZN opened at $176.28 on Thursday. The firm has a market cap of $273.39 billion, a PE ratio of 26.47, a P/E/G ratio of 1.41 and a beta of 0.25. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The business has a fifty day simple moving average of $190.88 and a 200-day simple moving average of $184.54. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. As a group, equities analysts predict that Astrazeneca Plc will post 10.26 EPS for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.